Decades of drug price inflation have reached a fever pitch that finally has lawmakers in both political parties itching for action. But, as is often the case in Washington, good intentions don't always equate to good ideas or outcomes.
The government's drug price controls enacted last year in the Inflation Reduction Act are already killing innovation, as drug makers abandon research into therapies for certain cancers and blindness. A study warns the law will result in 135 fewer new drugs, and that may well be a conservative estimate.
Comments